Cargando…
Multicenter study of the clinicopathological features and recurrence risk prediction model of early-stage breast cancer with low-positive human epidermal growth factor receptor 2 expression in China (Chinese Society of Breast Surgery 021)
BACKGROUND: : Breast cancer with low-positive human epidermal growth factor receptor 2 (HER2) expression has triggered further refinement of evaluation criteria for HER2 expression. We studied the clinicopathological features of early-stage breast cancer with low-positive HER2 expression in China an...
Autores principales: | Xin, Ling, Wu, Qian, Zhan, Chongming, Qin, Hongyan, Xiang, Hongyu, Xu, Ling, Ye, Jingming, Duan, Xuening, Liu, Yinhua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276244/ https://www.ncbi.nlm.nih.gov/pubmed/35274907 http://dx.doi.org/10.1097/CM9.0000000000002056 |
Ejemplares similares
-
Neoadjuvant therapy for early human epidermal growth factor receptor 2 positive breast cancer in China: A multicenter real-world study (CSBrS-015)
por: Cheng, Yuanjia, et al.
Publicado: (2022) -
Clinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy
por: Xu, Ling, et al.
Publicado: (2017) -
Clinicopathological analysis of early-stage breast cancer patients that meet indications for BRCA1/2 genetic testing
por: Xiang, Hongyu, et al.
Publicado: (2020) -
Correlation between Androgen Receptor Expression in Luminal B (HER–2 Negative) Breast Cancer and Disease Outcomes
por: Yang, Fan, et al.
Publicado: (2022) -
A retrospective prognostic evaluation analysis using the 8th edition of American Joint Committee on Cancer (AJCC) cancer staging system for luminal A breast cancer
por: Ye, Jingming, et al.
Publicado: (2017)